News Search

Dr. Alan S. Brown, said that "overall, the investigators have done a commendable job." However, he also noted that the "findings could also be influenced by treatment-seeking behaviors."

“This is undeniably a major advance,” said Dr. Jeffrey Lieberman. But he cautioned much is still unknown about the drug, particularly regarding its long-term use.

The FDA is set to approve SPRAVATOTM, an esketamine nasal spray that could help certain patients with severe depression. Dr. Drew Ramsey explains.

Dr. John Mann and colleagues followed 663 young adults who were at high risk for suicidal behavior because their parents had been diagnosed with mood disorders.